Exploratory Study to Estimate the Prophylactic Efficacy of Palivizumab in Healthy Adult Participants Inoculated With RSV
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT04540627 |
Recruitment Status :
Completed
First Posted : September 7, 2020
Results First Posted : October 4, 2021
Last Update Posted : October 4, 2021
|
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Study Type | Interventional |
---|---|
Study Design | Allocation: Randomized; Intervention Model: Parallel Assignment; Masking: Triple (Participant, Care Provider, Investigator); Primary Purpose: Other |
Condition |
Healthy Adult Participants |
Interventions |
Drug: Palivizumab Drug: Placebo Other: RSV-A Memphis 37b virus |
Enrollment | 56 |
Recruitment Details | |
Pre-assignment Details |
The study was conducted in 2 parts: Part 1 (PK sentinel part) and Part 2 (viral challenge part). Part 1: Open-label. This part of the study was used to determine the dose of Palivizumab IV for Part 2 (8 or 15 mg/kg). Part 2: Double-blind, randomized, and placebo-controlled. Participants received a single IV dose of either Palivizumab (8 mg/kg, as finally determined in Part 1) or a placebo and were subsequently challenged with an RSV-A strain. |
Arm/Group Title | Open-label Palivizumab (Part 1) | Double-blind Placebo (Part 2) | Double-blind Palivizumab (Synagis™) (Part 2) |
---|---|---|---|
![]() |
Sterile vial 50mg/0.5mL Palivizumab: Liquid solution in sterile water for injection (final concentration of 20mg/mL), intravenous infusion, single dose of 8mg/kg, administered at a rate of 1mL/min |
Sodium Chloride 0.9% Solution (Normal Saline) Placebo: Sodium Chloride 0.9% Solution (Normal Saline), intravenous infusion, single dose of 0mg/Kg, administered at a rate of 1mL/min RSV-A Memphis 37b virus: Single Intranasal Virus Dose (challenge dose is approximately 4.5log10 PFU) |
Sterile vial 50mg/0.5mL Palivizumab: Liquid solution in sterile water for injection (final concentration of 20mg/mL), intravenous infusion, single dose of 8mg/kg, administered at a rate of 1mL/min RSV-A Memphis 37b virus: Single Intranasal Virus Dose (challenge dose is approximately 4.5log10 PFU) |
Period Title: Open-label Treatment: PK Sentinel | |||
Started | 6 [1] | 0 [2] | 0 [2] |
Completed | 6 | 0 | 0 |
Not Completed | 0 | 0 | 0 |
[1]
Participants were not enrolled in this arm in the double-blind period.
[2]
Participants were not enrolled in this arm in the open-label period.
|
|||
Period Title: Double-blind Treatment: Viral Challenge | |||
Started | 0 [1] | 25 [2] | 25 [2] |
Completed | 0 | 25 | 25 |
Not Completed | 0 | 0 | 0 |
[1]
Participants were not enrolled in this arm in the double-blind period.
[2]
Participants were not enrolled in this arm in the open-label period.
|
Arm/Group Title | Open-label Palivizumab (Part 1) | Double-blind Placebo (Part 2) | Double-blind Palivizumab (Synagis™) (Part 2) | Total | |
---|---|---|---|---|---|
![]() |
Sterile vial 50mg/0.5mL Palivizumab: Liquid solution in sterile water for injection (final concentration of 20mg/mL), intravenous infusion, single dose of 8mg/kg, administered at a rate of 1mL/min |
Sodium Chloride 0.9% Solution (Normal Saline) Placebo: Sodium Chloride 0.9% Solution (Normal Saline), intravenous infusion, single dose of 0mg/Kg, administered at a rate of 1mL/min RSV-A Memphis 37b virus: Single Intranasal Virus Dose (challenge dose is approximately 4.5log10 PFU) |
Sterile vial 50mg/0.5mL Palivizumab: Liquid solution in sterile water for injection (final concentration of 20mg/mL), intravenous infusion, single dose of 8mg/kg, administered at a rate of 1mL/min RSV-A Memphis 37b virus: Single Intranasal Virus Dose (challenge dose is approximately 4.5log10 PFU) |
Total of all reporting groups | |
Overall Number of Baseline Participants | 6 | 25 | 25 | 56 | |
![]() |
[Not Specified]
|
||||
Age, Continuous
Mean (Standard Deviation) Unit of measure: Years |
|||||
Number Analyzed | 6 participants | 25 participants | 25 participants | 56 participants | |
25.67 (2.58) | 28.16 (6.30) | 26.76 (5.83) | 26.86 (4.90) | ||
Sex: Female, Male
Measure Type: Count of Participants Unit of measure: Participants |
|||||
Number Analyzed | 6 participants | 25 participants | 25 participants | 56 participants | |
Female |
2 33.3%
|
12 48.0%
|
5 20.0%
|
19 33.9%
|
|
Male |
4 66.7%
|
13 52.0%
|
20 80.0%
|
37 66.1%
|
|
Race (NIH/OMB)
Measure Type: Count of Participants Unit of measure: Participants |
|||||
Number Analyzed | 6 participants | 25 participants | 25 participants | 56 participants | |
American Indian or Alaska Native |
0 0.0%
|
0 0.0%
|
1 4.0%
|
1 1.8%
|
|
Asian |
0 0.0%
|
0 0.0%
|
0 0.0%
|
0 0.0%
|
|
Native Hawaiian or Other Pacific Islander |
0 0.0%
|
0 0.0%
|
0 0.0%
|
0 0.0%
|
|
Black or African American |
0 0.0%
|
0 0.0%
|
2 8.0%
|
2 3.6%
|
|
White |
4 66.7%
|
23 92.0%
|
20 80.0%
|
47 83.9%
|
|
More than one race |
2 33.3%
|
2 8.0%
|
2 8.0%
|
6 10.7%
|
|
Unknown or Not Reported |
0 0.0%
|
0 0.0%
|
0 0.0%
|
0 0.0%
|
Name/Title: | Director of Clinical Trials |
Organization: | mAbxience Research SL |
Phone: | +34917711500 |
EMail: | susana.millan@mabxience.com |
Responsible Party: | mAbxience Research S.L. |
ClinicalTrials.gov Identifier: | NCT04540627 |
Other Study ID Numbers: |
MB05-P-01-20 |
First Submitted: | July 24, 2020 |
First Posted: | September 7, 2020 |
Results First Submitted: | June 22, 2021 |
Results First Posted: | October 4, 2021 |
Last Update Posted: | October 4, 2021 |